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Abstract
Objectives We hypothesized that non-contrast-enhanced
PETRA (pointwise encoding time reduction with radial acqui-
sition) MR (magnetic resonance) sequencing could be an al-
ternative to unenhanced computed tomography (CT) in
assessing cystic fibrosis (CF) lung structural alterations, as
well as compared agreements and concordances with those
of conventional T1-weighted and T2-weighted sequences.
Material and methods Thirty consecutive CF patients com-
pleted both CT and MRI the same day. No contrast injection
was used. Agreement in identifying structural alterations was
evaluated at the segmental level using a kappa test. Intraclass
correlation coefficients (ICC) and Bland-Altman analysis
were used to assess concordances and reproducibility in
Helbich-Bhalla disease severity scoring.
Results Agreement between PETRA and CT was higher than
that of T1- or T2-weighted sequences, notably in assessing the
segmental presence of bronchiectasis (Kappa = 0.83; 0.51;
0.49, respectively). The concordance in Helbich-Bhalla scores
was very good using PETRA (ICC=0.97), independently from
its magnitude (mean difference (MD)= -0.3 [-2.8; 2.2]), where-
as scoring was underestimated using both conventional T1 and
T2 sequences (MD=-3.6 [-7.4; 0.1]) and MD=-4.6 [-8.2; -
1.0], respectively). Intra- and interobserver reproducibility were
very good for all imaging modalities (ICC=0.86-0.98).
Conclusion PETRA showed higher agreement in describing
CF lung morphological changes than that of conventional se-
quences, whereas the Helbich-Bhalla scoring matched closely
with that of CT.
Key Points
• Spatial resolution of lung MRI is limited using non-ultra-
short TE MRI technique
• Ultra-short echo time (UTE) technique enables submillime-
ter 3D-MRI of airways
• 3D-UTE MRI shows very good concordance with CT in
assessing cystic fibrosis
• Radiation-free 3D-UTE MRI enables the Helbich-Bhalla
scoring without a need for contrast injection
Keywords Lung .MRI . CT . Cystic fibrosis . Ultra-short
echo time
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Introduction
Cystic fibrosis (CF) is caused by the cystic fibrosis transmem-
brane conductance regulator (CFTR) gene mutation and rep-
resents one of the most frequent and lethal inherited diseases
in Caucasians [1]. Chronic lung disease is the main manifes-
tation and represents more than 90 % of CF morbidity and
mortality. However, thanks to innovative treatments, the me-
dian life expectancy of CF patients has reached 41 years [2],
and today there are more adult CF patients than there are those
younger than 18 years old.
Computed tomography (CT), owing to its high spatial res-
olution and contrast, is the standard of reference in imaging for
depicting lung structural alterations. CT can detect subtle
modifications such as bronchiectasis and trapped air that occur
early in the course of the disease and develop before alteration
in spirometry-measured lung function [3]. Conversely, chest
radiography was shown to detect 5 % of mucous plugging and
about 40 % of bronchiectasis [4]. In 50 % of patients without
change in lung function, it has been reported that CTwas able
to detect structural worsening of the disease [5]. Without the
use of CT, the diagnosis of bronchiectasis can be delayed by
three years [6]. Early detection is essential, because further
irreversible lung damage may be prevented by treatment.
However, CT is an ionizing technique, and a recent large ep-
idemiological study has shown that repeated low radiation
exposures, accrued in amounts as low as 1.1 mGy per year,
generate a 10.45 per Gy excess risk for death from chronic
myeloid leukemia in adults [7].
Proton MRI has shown promise in describing CF pulmo-
nary changes without use of radiation [8, 9]. However, in
using conventional techniques, i.e. non-ultra-short TE, there
is a need for contrast application that may balance this advan-
tage in MRI safety because of potential side effects following
either immediate or iterative procedures [10, 11]. In addition,
the evaluation of structural alterations remains less accurate
than that of CT. In particular, there is a known inability to
detect parenchymal modifications and bronchiectasis, a cru-
cial feature in CF [12]. Thus, modified scorings systems have
been proposed where bronchiectasis was mixed together with
either wall thickening [13] or mucus plugging [13–15] in or-
der to improve concordance with CT. However, using
unmodified evaluations, Ciet and colleagues have recently
pointed out a 33 % sensitivity in diagnosing severe bronchi-
ectasis using a robust T2 sequence [16], whereas Sileo and
colleagues reported a 36 % concordance in assessment of
bronchial paths using a combination of T2 and post-contrast
T1 examinations [17].
Recent advances in three-dimensional ultra-short echo time
(3D-UTE) imaging have shown promise in improving non-
contrast lung MR imaging quality [18–20]. PETRA
(pointwise encoding time reduction with radial acquisition)
is a novel 3D-sequence that has been recently demonstrated
to reach submillimeter MR imaging of the lung [19]. Due to
improved spatial resolution, we hypothesized that PETRA
could improve agreement with CT in depicting structural al-
terations as compared to either T1- or T2-weighted conven-
tional pulse sequences previously reported in the field of cys-
tic fibrosis. Since CT is the standard of reference in CF, we
aimed at evaluating whether non-contrast-enhanced MRI
could be an alternative to unenhanced CT in assessing a na-
tive, unmodified Helbich scoring [21, 22]. Therefore, the aims
of the study were (i) to assess the agreement of proton MRI at
the segmental level in assessing structural-CF lung changes
using three sequences: PETRA, T1-weighted, and T2-
weighted acquisitions with CT as gold standard, (ii) to assess
the concordance in assessing a global lung disease severity by
using the Helbich score [21], (iii) to assess intra- and interob-
server reproducibility, and (iv) to assess correlation with lung
function.
Materials and methods
Patients
The study was performed between September 2014 and April
2015 in a single institution. All consecutive patients who were
followed-up for CF were asked to participate during their rou-
tine annual visit. In our institution, imaging is performed for
that purpose starting from the age of 6-year-old, using either
chest radiograph, CT, orMRI [23–26]. The period of inclusion
was planned so that at least 30 consecutive patients would
have to perform CT. The diagnosis of CF was confirmed by
a characteristic phenotype in conjunction with sweat test and/
or genotyping. CT and MRI had to be performed on the same
day. For the study purpose, patients hospitalized for an acute
complication (hemoptysis, acute broncho-pneumonia requir-
ing intravenous antibiotic therapy, pancreatitis, or hepato-
biliary complication) were not enrolled. Patients were also
excluded if they had a contraindication to undergoing MRI,
such as iron material, a heart pacemaker, or claustrophobia.
The local ethics committee approved the study and all patients
gave written informed consent. All co-authors had full control
over the data at each step of the study.
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CTand MR protocols
All imaging modalities were performed in the supine position
without contrast injection. Low-dose CT of the chest was ac-
quired on a Somatom Definition 64 (Siemens, Erlangen,
Germany). Tube voltage was adapted to patient weight, i.e.
80 kV for patients <35 kg and 110 kV for patients >35 kg. A
modulating tube current (CareDose4D; Siemens Medical
Solutions) with an effective reference tube current of 50
mAs was used. Other CT scan parameters were: 75-ms rota-
tion time and 1-mm collimation. Patients were instructed oral-
ly along with maneuver training before and during examina-
tion to hold their breath at functional residual capacity (FRC)
[27]. CT datasets were reconstructed with a 1-mm reconstruc-
tion section thickness, 1-mm reconstruction interval. Field-of-
view (FOV) was adapted to patient’s size, while the matrix
was 512×512, voxel size= (0.6-0.7 mm)3. The effective dose
ranged from 1.2 to 1.5 mSv.
MR examinations were performed on a 1.5-TeslaMR scan-
ner (MAGNETOM Avanto, Siemens Healthcare, Erlangen,
Germany). Acquisitions were performed in the axial plane
using a 12-channel thorax/spine coil. We used previously pub-
lished sequence parameters for each MR sequence. PETRA
was acquired under free-breathing with respiratory gating at
FRC. Sequence parameters were TR/TE=4.1/0.07 ms, α (flip
angle)=6°, acquisition time=8 to 15 minutes (depending on
patient breathing frequency), averaging = 1, voxel size of
(0.86 mm)3 [19]. T1-weighted (VIBE) fast sequence was ob-
tained under breath-holding when possible or by respiratory
synchronization when breath-holdings were not achievable
[28]. T1-weighted parameters were TR/TE= 3.8/1.18 ms,
α=8°, acquisition time= 20 seconds, averaging = 1, voxel
size = 1.6 × 1.6 × 4 mm3. T2-weighted sequence (BLADE)
was acquired under respiratory triggering. Parameters were
TR/TE=2000/27 ms, α=150°, acquisition time=7-16 min,
averaging=1, voxel size=1.8×1.5×5 mm3 [12] .
Imaging analysis of CF structural alterations
All CT and MR datasets were anonymized and analyzed in
random order independently by two observers with four (ob-
server 1) and 30 (observer 2) years of experience in chest im-
aging. Both observers were blinded from clinical and function-
al data. First, a segmental analysis was performed considering a
total of 18 broncho-pulmonary segments, as described by
Bhalla and colleagues [4] and Helbich and colleagues [21].
Each segment was analyzed in random order, with one segment
analyzed per round of evaluation. For this, the presence of
structural alterations was quoted on a binary scale considering
that an abnormality was Babsent^ (=0) and Bpresent^ (>0). In
addition, whether an abnormality was noticed, the severity was
graded using the Helbich (modified Bhalla) score [4, 21]
(Supplemental Table 1). Briefly, the evaluation of airways
included wall thickening, bronchiectasis, mucous plugging
and sacculation/abscess; parenchymal abnormalities included
collapse/consolidation, emphysema, bullae, and mosaic of at-
tenuation. Definitions were those of the Fleishner Society glos-
sary [29]. Second, lung abnormalities described at the segmen-
tal level were synthetized into a whole-lung severity score
using the Helbich-Bhalla scoring system [21]. The same eval-
uation was performed eight weeks later by observer 2 and intra-
and inter-observer agreements were determined.
Imaging analysis of artifacts
The presence of cardiac and respiratory motion artifacts (blur-
ring, streaks) was assessed by observer 2 using a Likert scale
as proposed by Johnson et al. [18]: 0=minimal/none; 1=pres-
ent but mild, i.e. local and does not obscure normal lung anat-
omy; 2=moderate, local and obscures normal lung anatomy;
3 = severe, diffuse and renders images non-diagnostic. We
used anatomical structures that were expected to be readily
visible in all imaging modalities to assess normal anatomy,
i.e. the heart, the diaphragm, and the rib cage contours. For
CT imaging, additional assessment of beam hardening arti-
facts was performed using the same visual grading.
Statistical analysis
Statistical analyses were performed using NCSS (Kaysville,
Utah, USA) and MedCalc (Acacialaa, Osten, Belgium) soft-
wares. The mean score between observers was used for all
analyses. Correlations were assessed using Spearman’s rank
test. Agreement with CT to assess the presence or absence of
a lung structural abnormality was determined at the segmental
level using a kappa test.McNemar’s tests were used to compare
the proportion of structural abnormalities on CTandMRI. A p-
value inferior to 0.05 was considered significant. Intraclass
correlation coefficient (ICC) and Bland-Altman plots were
used for the evaluation of concordances regarding disease se-
verity scores and to assess inter- and intraobserver reproduc-
ibility. Kappa or ICC values indicated null (=0), slight (<0.20),
fair (0.21–0.40), moderate (0.41–0.60), good (0.61–0.80) or
very good (0.81 or greater) concordance [30]. ICCs with mea-
surement of consistency were produced along with absolute
agreement to take into account for potential systematic variabil-
ity. Finally, 95 % confidence intervals (CI 95 %) were used to
check for possible overlap between kappa and ICC values.
Results
Population characteristics
Demographic and functional data from the population studied
are reported in Table 1. A total of 32 patients or their parents,
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addressed for their routine annual visit, were approached. CT
was feasible in all patients andMRI was completed in 30. One
patient suffered from claustrophobia. In the absence of seda-
tion, one 6-year-old child did not remain sufficiently motion-
less to complete the MR examination.
Of the 30 patients who completed both CT and MRI on the
same day, 14 were younger than 18 years old, while 16 were
above the age of 18. Mean age was 22.6±9.6 years, ranging
from 9 to 48 years old. There were 14 males (mean age=25.0
±9.2) and 16 females (mean age=20.6±9.8), without signif-
icant difference in age between males and females (p=0.14).
Sixteen patients were homozygous for the ΔF508 mutation.
Seven patients had severe pulmonary function alteration with
FEV1% of <50 %. Two patients were found to have
syngomyelia. All patients were clinically stable, though dis-
ease severity showed a wide range of severity at CT, as
assessed by Helbich-Bhalla scores ranging from 0 to 23
(mean=13.6±5.5).
Agreement of MRI in assessing structural alterations
at the segmental level
A total of 540 broncho-pulmonary segments in 30 patients
were examined. The most common structural alteration at
CT was the presence of mosaic of attenuation (324/540),
followed by bronchiectasis (320/540), mucus plugging (306/
540), peribronchial thickening (274/540), and sacculation/
abscesses (89/540). Collapse and consolidation were reported
in 59/540 of the segments, whereas emphysema was present
in 13/540 and bullae in only 4/540. PETRA showed higher
agreement than either T1-weighted or T2-weighted sequences
in assessing bronchial and parenchymal alterations (Table 2).
The proportion of structural abnormalities was also signifi-
cantly reduced on conventional pulse sequences (p<0.01,
McNemar test) except for bullae (n=4). Regarding airways,
PETRA imaging showed good to very good agreement in
describing large airway abnormalities (Table 2, Fig. 1).
Owing to submillimeter spatial resolution, a clear delineation
of airway walls and lumen was possible, including low-grade
modifications (Figs. 2 and 3). Despite very good agreement
(Kappa=0.83 [0.78; 0.87]), the proportion of bronchiectasis
was significantly inferior to that of CT (p<0.05, McNemar
test). However, agreement was better than with T1- and T2-
weighted sequences, with no overlap in CI 95 % of kappa
values. A sufficient parenchymal signal was allowed by the
PETRA sequence, showing very good agreement in assessing
CT mosaic of attenuation (kappa=0.86) (Fig. 2). However,
the agreement of PETRA to detect emphysema was moderate
(kappa=0.44). Table 3 shows that both CT and MR evalua-
tions were reproducible (ICC=0.66-0.99)
Table 1 Characteristics of 30
patients with cystic fibrosis Gender M/F 14M / 16F
Age 22.6 ± 9.6 (9 - 48)
BMI 22.6 ± 3.8(15.4 - 32.5)
Mutations ΔF508 homozygous 16
ΔF508 / other mutation 14
Chronic bacterial infection Pseudomonas aeruginosa 11
MR-SA 3
MS-SA 4
ABPA 1
S. maltophilia 6
None 4
Co-morbidities Syringomyelia (yes/no) 2/25
Pancreatic insufficiency (yes/no) 19/11
Hepato-biliary disease (yes/no) 5/25
Respiratory function FEV1 (%) 64.0 ± 23.0(23 - 106)
FEV1/FVC 71.5 ± 12.1(51.1 - 94.6)
RV (%) 154.0 ± 67.0(80 - 357)
TLC (%) 100.2 ± 14.3(82 - 134)
CT Helbich-Bhalla score 13.6 ± 5.5(0 - 23)
Data are numbers for categorical variables and means for continuous variables associated with standard deviation.
Data between parentheses are minimum/maximum interval. Legend:MMale; F Female; BMI Body mass index;
MR-SA Methicillin-resistant Staphilococcus aureus; MS-SA Methicillin-sensitive Staphilococcus aureus; ABPA
Allergic broncho-pulmonary aspergillosis; FEV1 Forced expiratory volume in 1 second; FVC Functional vital
capacity; RV Residual volume; TLC Total lung capacity; CT Computed tomography
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Concordance between CT and MRI in calculating
the Helbich-Bhalla score
PETRA showed good to very good agreement with CT in
assessing all items included in the Helbich-Bhalla score
(ICC=0.65-0.98), whereas the concordance in the overall se-
verity score was very good (ICC=0.97) (Table 4). The mean
difference between values was -0.3 [-2.8; 2.2] using PETRA
independently from the magnitude of score (Fig. 4). With
conventional T1- or T2-weighted sequences, the mean differ-
ences were -3.6 [-7.4; -0.1] and -4.6 [-8.2; -1.0] respectively,
indicating a systematic underestimation without dominance
toward low or high values. ICCs with measurement of
consistency were very good using T1- and T2-weighted se-
quences, and good when considering absolute agreement
(ICC=0.71 and 0.65, respectively). There was no overlap in
CI 95 % with ICCs of PETRA, demonstrating a significantly
higher degree of concordance. These results are in keeping
Table 2 Agreement and comparison between CT and MRI to assess the presence of structural alterations in 540 broncho-pulmonary segments
CT PETRA T1 T2
%abnormal %abnormal Kappa CI95% %abnormal Kappa CI95% %abnormal Kappa CI95%
Bronchial alterations
Peribronchial thickening 50.7 49.3 0.83 [0.78 ; 0.87] 30.9* 0.60 [0.48; 0.63] 25.7* 0.48 [0.43; 0.58]
Bronchiectasis 59.3 53.2* 0.83 [0.78 ; 0.87] 31.5* 0.51 [0.41 ; 0.55] 29.4* 0.49 [0.38;0.54]
Sacculation/abscess 16.4 9.5* 0.83 [0.78 ; 0.90] 6.8* 0.59 [0.44 ; 0.70] 6.5* 0.51 [0.34 ; 0.63]
Muccus plugging 56.7 59.5 0.82 [0.78 ; 0.86] 45.1* 0.73 [0.68 ; 0.80] 42.9* 0.70 [0.58 ; 0.70]
Parenchymal alterations
Collapse/consolidation 10.9 9.5 0.88 [0.82 ; 0.94] 6.5* 0.62 [0.59 ; 0.86] 6.8* 0.64 [0.54 ; 0.83]
Mosaic 60.0 59.5 0.86 [0.81 ; 0.90] 3.4* 0.04 [0.01 ; 0.08] 3.4* 0.04 [0.00; 0.08]
Bullae 0.7 0.6 0.86 [0.61 ; 1.00] 0.1 0.00 [0.00 ; 0.00] 0.0 0.00 [0.00 ; 0.00]
Emphysema 2.4 2.1 0.44 [0.25 ; 0.78] 0.3* 0.14 [-0.07 ; 0.26] 0.7* 0.20 [0.00; 0.40]
Agreement between CT and MRI is performed using kappa test with 95 % confidence interval (CI95%) Comparison between CT and MRI was
performed using McNemar test.* indicates a p-value < 0.05
Fig. 1 Axial CT (a, c) and corresponding PETRA (b, d) lung sections in a
14-year-old female with cystic fibrosis. On A and B images, black arrows
indicate a nodular consolidation and white arrows a peripheral severe
(grade 3) bronchiectasis with sacculations. On C and D images, white
arrows indicate a fine, submillimeter right major fissure and black/white
arrow heads indicate concordant variations in lung parenchyma attenuation
(c) and signal (d). These features demonstrate that both submillimeter
resolution and sufficient lung signal are reached using PETRA
Fig. 2 Axial section of the right upper lobe in a 27-year-old male using
CT (a), PETRA (b), T1 (c) and T2 (d) examinations. There are mucous
plugs with a Bfinger-in-glove^ appearance, visible in all imaging modal-
ities. On T1-weighted (c) imaging, intra-pulmonary airways are not dis-
tinguishable owing to susceptibility artifacts. On T2-weighted (d) imag-
ing there is partial visibility of intrapulmonary airways. Due to a lack of
spatial resolution, bronchi contours are blurred and there is subjective
impression of wall thickening (grade 1) with associated narrowing of
lumen. On CT (a) and PETRA (b) exams, bronchi wall appear to be thin
(grade 0), whereas there is moderate lumen bronchiectasis (grade 1). The
bronchial generation is directly accounting from the segmental level to
the lung periphery (superior to the 6th bronchial generation)
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with that from the segmental analyses (Table 2), whereas
intra- and interobserver reproducibility in overall scores were
found very good on both CT and MRI, no matter the imaging
modality (ICC=0.86-0.98).
Imaging artifacts
Results of all imaging modalities were considered to be of
diagnostic quality (Supplemental Table 2). Regarding cardiac
motion artifacts, PETRA was the sole sequence devoid of
heart motion artifacts, whereas they were constant though
mild using both CT and conventional MR examinations.
Conversely, PETRA showed both blurring artifacts (average
score 0.9 ± 0.3) and streak artifacts (1.0 ± 0.0). The streaks
started from the sternum and the posterior attachment of the
diaphragm. Conversely, lung motion artefacts were absent on
CT imaging though beam-hardening artefacts were constant
(1.0±0.0) on CT imaging due to attenuation by the rib cage.
Correlation with lung function
Similar correlation coefficients were found between FEV1
(%) and Helbich scores on CT and MRI evaluations.
However, CT and PETRA shared additional significant corre-
lation with residual volume (RV%) (Table 5).
Discussion
To our knowledge, the ability of 3D UTE MRI to assess air-
way disease in cystic fibrosis has not yet been reported. Our
results have shown good to very good agreement to detect CF-
lung structural alterations at the segmental level, in particular
bronchiectasis and parenchymal modifications, whereas a
global disease severity score (Helbich-Bhalla) could be calcu-
lated without the need of contrast injection and with very good
concordance between 3D-CT and 3D-MRI (ICC=0.97).
Fig. 3 Axial section of the right upper lobe in a 23-year-old male using
CT (a), PETRA (b), T1 (c) and T2 (d) examinations. Mild (grade 1) to
severe (grade 3) bronchiectasis is shown, as well as no (grade 0) to severe
(grade 3) degree of wall thickening. Note the good visibility of a thin-
walled (grade 0), dilated bronchi (grade 3) indicated by the green arrow
on (a) and (b) images. This abnormality was unnoticed on (c) and (d)
images because the airway wall was below the available spatial resolu-
tion. Submillimeter normal fissure is also visible on A and B but not C
and D evaluations (white arrows)
Table 3 Intra- and interobserver reproducibility of MRI to assess disease severity by using CT and MRI at the segmental level
CT PETRA T1 T2
ICCintra ICCinter ICCintra ICCinter ICCintra ICCinter ICCintra ICCinter
Bronchial alterations
Wall thickening severity 0.79 0.72 0.87 0.72 0.82 0.74 0.88 0.68
Bronchiectasis severity 0.91 0.87 0.92 0.87 0.89 0.82 0.92 0.78
Sacculation/abscess (present/absent) 0.83 0.72 0.84 0.74 >.99 0.72 0.99 0.70
Muccus plugging (present/absent) 0.86 0.81 0.89 0.83 0.97 0.79 0.94 0.79
Bronchial generation involved 0.87 0.89 0.95 0.85 0.97 0.81 0.95 0.78
Parenchymal alterations
Collapse/consolidation severity 0.95 0.72 0.92 0.79 0.97 0.72 0.98 0.73
Mosaic of attenuation (present/absent) 0.95 0.85 0.98 0.84 >.99 >.99 0.97 0.75
Bullae (present/absent) 0.66 0.79 0.66 0.85 NA NA NA NA
Emphysema (present/absent) 0.90 0.68 0.66 0.61 0.49 0.00 NA 0.00
ICCintra Intraobserver reproducibility assessed by intraclass correlation coefficient
ICCinter Interobserver reproducibility assessed by intraclass correlation coefficient
NA not applicable
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The emergence of UTE MRI is a novel and promising
development in the field of lung imaging with no radiation
dose [18–20]. Recent articles indicates that 3D-UTE is better
than conventional sequences to assess lung nodules and pul-
monary embolism [31, 32]. The PETRA sequence is an orig-
inal noiseless approach to the UTE principle in which the
peripheral part of the k-space is acquired in radial mode,
whereas the central part is acquired point by point in
Cartesian mode. This combination was shown to enable an
encoding time reduction and thus, get significantly more sig-
nal than standard UTE sequences, resulting in higher modu-
lation transfer function values using three T2-calibrated
Table 4 Concordance between
CT and MRI to assess disease
severity using Helbich-Bhalla
score in 30 patients
Petra T1 T2
ICC CI 95 % ICC CI 95 % ICC CI95%
Bronchial alterations
wall thickening severity 0.94 [0.92 ; 0.96] 0.80 [0.19 ; 0.93] 0.44 [-0.08 ; 0.77]
Bronchiectasis severity 0.90 [0.83 ; 0.96] 0.65 [0.03 ; 0.88] 0.45 [-0.11 ; 0.78]
Bronchiectasis extent 0.89 [0.82 ; 0.97] 0.57 [0.09 ; 0.86] 0.43 [-0.11 ; 0.78]
Sacculation/abscess extent 0.88 [0.84 ; 0.92] 0.53 [0.09 ; 0.79] 0.53 [0.11 ; 0.79]
Muccus plugging extent 0.81 [0.34 ; 0.94] 0.89 [0.60 ; 0.96] 0.88 [0.61 ; 0.96]
Bronchial generation involved 0.98 [0.97 ; 0.99] 0.33 [-0.06 ; 0.66] 0.37 [-0.04 ; 0.69]
Parenchymal alterations
Collapse/consolidation severity 0.95 [0.90 ; 0.98] 0.86 [0.69 ; 0.94] 0.93 [0.84 ; 0.97]
Mosaic extent 0.87 [0.96 ; 0.99] 0.07 [-0.11 ; 0.35] 0.11 [0.00 ; 0.25]
Bullae extent 0.89 [0.78 ; 0.95] 0.00 [-0.40 ; 0.42] 0.10 [-0.10 ; 0.20]
Emphysema extent 0.65 [0.35 ; 0.83] 0.00 [-0.29 ; 0.31] 0.18 [-0.20 ; 0.33]
Helbich-Bhalla score
Consistency 0.97 [0.96 ; 0.99] 0.92 [0.84 ; 0.95] 0.88 [0.76 ; 0.95]
Absolute agreement 0.97 [0.95 ; 0.98] 0.71 [-0.06 ; 0.92] 0.65 [-0.08 ; 0.89]
ICC Intraclass correlation coefficient. CI Confidence interval
Fig. 4 Bland-Altman analysis of Helbich-Bhalla scores obtained using
CT and MRI. From left to right, figures in the upper row show Helbich-
Bhalla scores obtained using CT (CTHelbich) plotted against those obtain-
ed using PETRA (PETRAHelbich), T1 (VIBEHelbich) and T2
(BLADEHlebich) sequences, respectively. The diagonal green line
corresponds to the line of equality. From left to right, figures on the lower
row are the corresponding difference of measurements plotted against
their average value, according to Bland-Altman analysis. The solid red
line corresponds to the mean difference. The dashed black lines corre-
spond to the upper and lower 95 % limits of agreement
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phantoms [33]. The gain in signal has been previously shown
to be sufficient in acquiring submillimeter lung MR airways
up to the sixth bronchial generation [19]. However, due to
unknown 3D-UTE contrasts from airway disease conditions,
there was no a priori evidence that it would be valuable to
decrease the voxel size as compared to existing clinical
methods. Therefore, in vivo evaluation in patients with CF
had to be performed.
In addition, respiratory synchronization systems are known
to be imperfect under disease conditions, and it has been
shown that noise is increased using a respiratory-gated T1-
VIBE sequence as compared to VIBE under breath-holding
[28]. Here, we have shown that streaking artifacts were pres-
ent in patients with CF, likely to be attributed to the radial part
of the PETRA acquisition in patients with a lesser degree of
compliance to respiratory synchronization than in healthy sub-
jects [19]. However, all examinations were diagnostically ac-
ceptable and in patients with a wide range of CF severity (CT
Helbich scores from 0 to 23), clinically relevant datasets of
MR lung volumes could be obtained with some novel features
that deserve a discussion.
First, the level of agreement in detecting lung structural
alterations was found to be good to very good up to the seg-
mental level, which is the level required to enable a reliable
assessment in both CT [4, 21] and MR [15] scorings. A clear
delineation between airway wall and lumen was obtained,
thanks to submillimeter voxel size, enabling readers to estimate
both bronchial thickening and dilatation with very good con-
cordance with CT (ICC=0.94 and ICC=0.90, respectively),
independently from the magnitude of this score. In this study,
results from T1 and T2 conventional sequences were in the
range of those from previous reports [12, 16, 17]. Using con-
ventional sequences, Tepper and colleagues have reported a
0.41 and 0.35 concordance with CT in assessing bronchiectasis
and air trapping, respectively [12]. In our study, 51 % and 54%
of bronchiectasis graded as 2 and 3 (severe) were surrounded
by thin walls, below the available spatial resolution, rendering
them invisible at both conventional examinations.
Second, PETRA allows an isotropic 3D voxel size, which
enables multiplanar reconstructions in a single, free-breathing
and noiseless acquisition. Using 2D sequences, several planes
have to be acquired, resulting in repeated breath-holding ma-
neuvers in patients suffering from dyspnea.
Third, the use of UTE MRI for lung imaging enables the
detection of modifications related to both increased and de-
creased signal variations as compared to normal lung paren-
chyma. This is of clinical importance since CF modifications
are related to both a productive Bplus^ process (mucous plug-
ging, consolidation) and a destructive Bminus^ process affect-
ing airways (bronchiectasis) and lung parenchyma (emphyse-
ma, bullae). Using the UTE principle, a very good concor-
dance was found to assess lung mosaic, whereas a moderate
agreement was found at the segmental level in assessing em-
physema (kappa = 0.44). Nevertheless, the interobserver
agreement to assess emphysema severity is known to be mod-
erate even using CT scanning [34].
Regarding overall Helbich-Bhalla scores, the levels of
concordance and limits of agreement of mean difference
(LOA) were within the range of those previously reported
between inspiratory and expiratory CT using the Brody II
system (ICC=0.99; LOA [-7; 8]) [27] or between CT and
ultralow dose CT using the Bhalla score (ICC=0.96; LOA
[-2; 4]) [35]. The latter alternative to conventional CT was
considered to be of similar diagnostic quality than the gold
standard technique. Using the recently developed
PRAGMA-CF score, LOA for air trapping was [-15; 15]
[36]. To date, imaging follow-up of patients with CF is
heterogeneous and not consensual across expert centers.
Guidelines recommend beginning the disease management
process as early as possible, before irreversible modification
may occur [23, 24, 26]. The best imaging modality to diag-
nose it would be CT, but there is a dilemma due to the
cumulated radiation risk of CT. To find a compromise, some
expert centers do not use MRI but rather chest radiography
alternating with CT [35]. In other centers, MRI is viewed as
the modality of choice to follow-up CF patients and CT is
Table 5 Correlation between
pulmonary function and Helbich-
Bhalla scores assessed using CT
and MRI
CT PETRA T1 T2
ρ p-value ρ p-value ρ p-value ρ p-value
FEVI (%) -0.78 <.001 -0.81 <.001 -0.75 <.001 -0.57 0.01
FVC (%) -0.68 <.001 -0.70 <.001 -0.58 0.01 -0.40 0.09
FEVI/FVC -0.52 0.008 -0.55 0.004 -0.54 0.02 -0.51 0.03
RV (%) 0.50 0.01 0.47 0.02 0.45 0.06 0.28 0.26
TLC (%) -0.02 0.93 -0.06 0.76 0.12 0.63 0.28 0.26
Data are rho coefficient correlation of Spearman. P-value < 0.05 indicates a significant correlation between
variables.
Legends: FEV1 Forced expiratory volume in 1 s; FVC Functional vital capacity; RV Residual volume; TLC Total
lung capacity
Eur Radiol
not performed [25]. Still other expert centers are alternating
the use of MRI with CT [12]. Therefore, the novel technique
could be added to existing MR protocols routinely used in
CF, in order to reach sufficient levels of information to as-
sess a reliable and reproducible contrast-free evaluation of
the CT scoring.
The study has some limitations. The generalizability of the
present study is impaired by the small sample size of the
population, and because it was a monocentric study. Further
evaluation including a multicenter design, several time points
during follow-up, and other clinical variables than the sole
PFTs are needed. Moreover, it could be also argued that
comparing two imaging modalities on the basis of a sole
global CT score does not suffice, depending on whether the
segmental severity scorings would match or not. This is why
the first end point of the study was the agreement of disease
alterations at a segmental level. In addition, there were only
two non-UTE sequences in our study, whereas their perfor-
mances at 3 Tesla should be worth evaluating [37, 38].
Though lung perfusion is an interesting and important point
to be evaluated in dedicated clinical situations, the use of
contrast injection is still a matter of debate for long-term
repeated usage. Recent study has raised concerns on deep
nuclei accumulation following protracted gadolinium-based
contrast injections [11].
In addition, MRI in general is inferior to CT in terms of
availability, acquisition speed, and contraindications such as
claustrophobia and iron materials. PETRA has also the dis-
advantage of lasting only about 10 minutes. Though this
period was clinically acceptable and well-tolerated, its avail-
ability in infants, who are prone to body movements in
addition to respiratory movements, is probably not realistic
without sedation [39]. However, the demand in imaging that
clinicians have to put into balance is far beyond the sole
biennial CT evaluation. Since CF patients are prone to suffer
from chronic sinusitis and to develop digestive tract cancers
[40], MRI offers the potential to combine MR of the lung
with MRI examinations of the sinuses and abdomen as an
alternative to the sole CT of the chest in some dedicated
clinical situations. Finally, by including PETRA into lung
MR protocols, a morpho-functional analysis could be
reached with high resolution using MRI alone [41, 42], in-
stead of a time-consuming and cost-effective combination of
CT plus MRI.
To conclude, non-contrast-enhanced PETRA shows good
agreement with CT in assessing the presence of both produc-
tive and destructive structural alterations, up to the segmental
level. Moreover, PETRA shows very good agreement with
CT, independently from the magnitude of score, to assess
CF-disease severity with submillimeter spatial resolution. A
safe, unenhanced, radiation-free imaging evaluation of the
lung should be available for life-long management, without
major penalty as compared to gold standard CT.
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